Yield10 Bioscience, Inc.

Safety Score

Market Cap $295.95K
Debt $996.00K
Cash $745.00K
EV $546.95K
FCF -$5.82M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$12.70M
EBIT	-$12.60M
ROA	-424%
FCF	-$5.82M
Equity	-$6.24M
Growth Stability	1
PE	-0.02
PB	-0.05
P/FCF	-0.05
P/S	0.39
Price/Cash	2.52
Debt/Equity	-0.16
Debt/FCF	-0.17
Net Margins	-761%
Op. Margins	-2K%
Sales Growth QoQ	50%
Sales CAGR	-20%
Equity CAGR	-6%
Earnings Growth YoY	-12%
Earnings Growth QoQ	31%

Sales CAGR 5Y	-27%
Equity CAGR 5Y	-19%
Earnings CAGR 3Y	-33%
Sales CAGR 3Y	-33%
Equity CAGR 3Y	-40%
Market Cap	$295.95K
Revenue	$750.00K
Assets	$2.97M
Total Debt	$996.00K
Cash	$745.00K
Shares Outstanding	580.28K
EV	546.95K
Safety Score	32%
Working Capital	-6.47M
Current Ratio	0.16
Shares Growth 3y	26%
Equity Growth QoQ	88%
Equity Growth YoY	-1K%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

SEC Filings

Direct access to Yield10 Bioscience, Inc. (YTEN) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Yield10 Bioscience, Inc. compare to its competitors?

Not enough data to generate a comparison chart between Yield10 Bioscience, Inc. and its competitors. Please check back later.

Peter Lynch's Chart

This chart shows the current pricing of Yield10 Bioscience, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Yield10 Bioscience, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Yield10 Bioscience, Inc..

Years

Calculation mode

= -$58M

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$5.8M	-$58M
DCF		-$5.3M	-$4.8M	-$4.4M	-$4M	-$3.6M	-$3.3M	-$3M	-$2.7M	-$2.5M	-$2.2M	-$22M
Value	-$58M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-1K%	-913%	-656%	-1K%	-2K%	-2K%	-1K%	-2K%	-3K%	-24K%	-761%
ROA	-	-73%	-95%	-55%	-112%	-51%	-66%	-54%	-166%	-369%	-424%
ROE	-	-182%	-119%	-80%	-161%	317%	-107%	-69%	-308%	582%	-

Bad Net Margins (-761.33%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-0	-0.1	-0.17
Debt over Equity	-	-	-	-	-	-	-	-	0	-0.4	-0.16
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.17)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.16)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2014	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	-7%	-55%	-19%	-41%	45%	-1%	-23%	-27%	-87%	-27%
Earnings YoY growth	-	-20%	-68%	42%	-15%	41%	-21%	8%	23%	7%	-
Equity YoY growth	-	-31%	-51%	112%	-58%	-172%	-333%	68%	-73%	-156%	-19%
FCF YoY growth	-	-6%	-31%	-47%	7%	-1%	0%	8%	22%	-12%	-